Showing results (851-860 of 1,032) with videos related to

Sort By:
Pageof 104
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
The Journal of Pain|June 3, 2025
Family caregiver observations of pain behaviors in infants and young children less than 3 years of ageKathryn E Gustafson, Kanecia O Zimmerman, Alexy Hernandez, et al.
Physical Review Letters|June 1, 2004
Exclusive measurement of quasifree proton-neutron bremsstrahlungM Volkerts, J C S Bacelar, M J van Goethem, et al.
Science Advances|June 10, 2026
Legacies of foundation species shape life after deathKai L Kopecky, Max C N Castorani, Ty Tuff, et al.
Journal of Medicinal Chemistry|March 31, 2012
Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interactionXiaoqi Chen, David J Kopecky, Jeff Mihalic, et al.
Plos One|June 16, 2012
Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoidsMartin Rossmeisl, Zuzana Macek Jilkova, Ondrej Kuda, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
American Heart Journal|March 30, 2006
Study of the Therapeutic Effects of Intercessory Prayer (STEP) in cardiac bypass patients: a multicenter randomized trial of uncertainty and certainty of receiving intercessory prayerHerbert Benson, Jeffery A Dusek, Jane B Sherwood, et al.
Scientific Reports|January 28, 2026
Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor modelsJan Kopecky, Julio Enríquez Pérez, Stevanus Jonathan, et al.
British Journal of Haematology|February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapySteven E Coutre, Megan Othus, Bayard Powell, et al.
Pageof 104